Rituximab in AChR subtype of myasthenia gravis: systematic review. Di Stefano V, Lupica A, Rispoli MG, Di Muzio A, Brighina F, Rodolico C. JNNP 2020; 91:392-395. Abstract Background: Myasthenia gravis (MG) is a chronic autoimmune disorder of the neuromuscular junction characterised by an autoantibody against acetylcholine receptor (AChR-Ab), autoantibody against muscle-specific kinase (MuSK-Ab), lipoprotein-related protein […]

via How effective is rituximab in refractory myasthenia gravis? — Neurochecklists Blog

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s